Vicki Moore

6 days ago | renalandurologynews.com | Vicki Moore

Prostate biopsy findings of Gleason grade group (GG) 1 or atypical small acinar proliferation (ASAP) may require monitoring, according to 2 studies presented at the American Urological Association 2025 annual meeting in Las Vegas, Nevada.

1 week ago | shorturl.at | Vicki Moore

Trastuzumab deruxtecan (T-DXd) improved survival outcomes when compared to ramucirumab and paclitaxel as second-line treatment in a phase 3 trial of patients with HER2-positive, metastatic gastric or gastroesophageal junction (GEJ) cancer.1,2 These results, from the phase 3 DESTINY-Gastric04 trial, support T-DXd as second-line standard care for this patient population, said Kohei Shitara, MD, of the National Cancer Center Hospital East in Kashiwa, Japan, who presented the results at the ASCO...

1 week ago | shorturl.at | Vicki Moore

Switching first-line therapy upon detection of ESR1 mutations can be beneficial for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, results from the phase 3 SERENA-6 trial suggest.1,2 The trial showed that patients who were receiving first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor had an improvement in progression-free survival (PFS) if they switched to treatment with camizestrant and a CDK4/6 inhibitor upon detection of ESR1...

1 week ago | shorturl.at | Vicki Moore

Adding tagitanlimab to treatment with gemcitabine and cisplatin (GP) can improve progression-free survival (PFS) in patients with recurrent or metastatic nasopharyngeal cancer (NPC), according to research presented at the ASCO Annual Meeting 2025.1These results suggest that tagitanlimab plus GP could be a new standard first-line treatment for recurrent or metastatic NPC, according to study presenter Haiqiang Mai, MD, PhD, of Sun Yat-sen University Cancer Center in Guangzhou, China.

1 week ago | cancertherapyadvisor.com | Vicki Moore

Switching first-line therapy upon detection of ESR1 mutations can be beneficial for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, results from the phase 3 SERENA-6 trial suggest.1,2 The trial showed that patients who were receiving first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor had an improvement in progression-free survival (PFS) if they switched to treatment with camizestrant and a CDK4/6 inhibitor upon detection of ESR1...